Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 …PipelineReview.com (press release)EAGAN, MN, USA I December 10, 2012 I All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination th…
In an experimental treatment that may be the only way they can save some people who have contracted a dangerous colon infection, out of desperation some Minnesota doctors are transplanting donated, human feces into their patients' colons.
Immunomedics Provides Clinical Updates on Subcutaneous Injections of …MarketWatch (press release)The complementarity-determining regions (CDRs) of veltuzumab are identical to rituximab, except for one amino acid residue, which appears to give veltuzu…
UPDATE: UTMC officials speak out about resuming the living donor kidney transplant program.
Times of IndiaDiabetes can up heart failure riskTimes of IndiaIn 2010-11, 45,000 people with the condition had heart failure – where the heart does not pump blood as effectively as it should, when the expected number would have been 27,300. The most co…
|
Presumed organ donor proposal unless deceased has stated otherwise receives …
Scottish Daily Record While they stressed that they are not against organ donation or the continued use of the drug ciclosporin, they said patients should be made more aware of the potential side-effects in order to make an informed choice. Ms Baillie said: “We know … |
Inform Genomics Transplant Product Shown to Predict Oral Mucositis with a High …MarketWatch (press release)Patients who underwent stem cell transplant from 2006-2011 were identified and after informed consent had their saliva collected with an FDA ap…
|
European Journal of Heart Failure Lauds BioControl Medical’s Research on …
EON: Enhanced Online News (press release) BUSINESS WIRE)–BioControl Medical has announced that the pilot clinical study of its CardioFit® vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial … |
Boston, MA — InformGenomics, Inc., a private company focused on developing novelplatforms of genomic-based personalized medicine products forcancer supportive care, presented results that demonstrate …
Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the results from a completed phase II study with the investigational FLT3 inhibitor,